Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits

Lipids in Health and Disease

Volumn 12, Issue 1, 2013, Pages

  Niimi, Manabu ^a   Keyamura, Yuka ^b   Nozako, Masanori ^b   Koyama, Takashi ^b   Kohashi, Masayuki ^b   Yasufuku, Reiko ^b   Yoshikawa, Tomohiro ^b   Fan, Jianglin ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Atherosclerosis; Atorvastatin; Hypercholesterolemia; Monocyte; Probucol

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PROBUCOL; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; CELL ADHESION; CELL COUNT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INHIBITION; ENDOTHELIUM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INTIMA; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MONOCYTE; NONHUMAN; RABBIT; SCANNING ELECTRON MICROSCOPY; TRIACYLGLYCEROL BLOOD LEVEL;

ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA; ATHEROSCLEROSIS; CELL ADHESION; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIETARY FATS; ENDOTHELIAL CELLS; HEPTANOIC ACIDS; HYPERCHOLESTEROLEMIA; MACROPHAGES; MALE; MONOCYTES; PLAQUE, ATHEROSCLEROTIC; PROBUCOL; PYRROLES; RABBITS; TRIGLYCERIDES; TUNICA INTIMA;

EID: 84886738605     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-12-166     Document Type: Article

References (26)

1. Macrophages in the pathogenesis of atherosclerosis. Moore KJ, Tabas I, Cell 2011 145 341 355 10.1016/j.cell.2011.04.005 21529710
2. Progress and challenges in translating the biology of atherosclerosis. Libby P, Ridker PM, Hansson GK, Nature 2011 473 317 325 10.1038/nature10146 21593864
3. Where are we with probucol: a new life for an old drug? Yamashita S, Matsuzawa Y, Atherosclerosis 2009 207 16 23 10.1016/j.atherosclerosis.2009.04. 002 19457483
4. A novel mechanism by which probucol lowers low density lipoprotein levels demonstrated in the LDL receptor-deficient rabbit. Naruszewicz M, Carew TE, Pittman RC, Witztum JL, Steinberg D, J Lipid Res 1984 25 1206 1213 6520542 (Pubitemid 15216876)
5. Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis. Nestel PJ, Billington T, Atherosclerosis 1981 38 203 209 10.1016/0021-9150(81)90117-9 7470200 (Pubitemid 11138620)
6. High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Ishigami M, Yamashita S, Sakai N, Hirano K, Arai T, Maruyama T, Takami S, Koyama M, Kameda-Takemura K, Matsuzawa Y, Eur J Clin Invest 1997 27 285 292 10.1046/j.1365-2362.1997.1040657.x 9134376 (Pubitemid 27163252)
7. Probucol promotes reverse cholesterol transport in heterozygous familial hypercholesterolemia. Effects on apolipoprotein AI-containing lipoprotein particles. Adlouni A, El Messal M, Saïle R, Parra H, Fruchart J, Ghalim N, Atherosclerosis 2000 152 433 440 10.1016/S0021-9150(99)00493-1 10998472
8. Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport. Yamamoto S, Tanigawa H, Li X, Komaru Y, Billheimer JT, Rader DJ, Circulation 2011 124 1382 1390 10.1161/CIRCULATIONAHA. 110.009704 21859969
9. Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism. Rinninger F, Wang N, Ramakrishnan R, Jiang XC, Tall AR, Arterioscler Thromb Vasc Biol 1999 19 1325 1332 10.1161/01.ATV.19.5.1325 10323786 (Pubitemid 29227654)
10. Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. Hirano K, Ikegami C, Tsujii K, Zhang Z, Matsuura F, Nakagawa-Toyama Y, Koseki M, Masuda D, Maruyama T, Shimomura I, Ueda Y, Yamashita S, Arterioscler Thromb Vasc Biol 2005 25 2422 2427 10.1161/01.ATV.0000185834.98941.3d 16151015 (Pubitemid 41552665)
11. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai C, Proc Natl Acad Sci USA 1987 84 5928 5931 10.1073/pnas.84.16.5928 3475709
12. Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Daugherty A, Zweifel BS, Schonfeld G, Br J Pharmacol 1989 98 612 618 10.1111/j.1476-5381.1989.tb12635.x 2819336 (Pubitemid 19245770)
13. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. Yamashita S, Hbujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T, Matsuzawa Y, J Atheroscler Thromb 2008 15 292 303 10.5551/jat.E610 19060422
14. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Tobert JA, Nat Rev Drug Discov 2003 2 517 526 10.1038/nrd1112 12815379 (Pubitemid 37361744)
15. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists' (CTT) Collaborators, Lancet 2005 366 1267 1278 16214597
16. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R, Cholesterol Treatment Trialists' (CTT) Collaboration, Lancet 2010 376 1670 1681 10.1016/S0140-6736(10)61350-5 21067804
17. Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Brautbar A, Ballantyne CM, Nat Rev Cardiol 2011 8 253 265 10.1038/nrcardio.2011.2 21321561
18. Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia. Inagaki M, Nakagawa-Toyama Y, Nishida M, Nakatani K, Nakaoka H, Kawase M, Kawase R, Tsubakio-Yamamoto K, Masuda D, Ohama T, Matsuyama A, Ishigami M, Komuro I, Yamashita S, J Atheroscler Thromb 2012 19 643 656 10.5551/jat.12807 22785024
19. Guidelines for the management of familial hypercholesterolemia. Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, Nohara A, Bujo H, Yokote K, Wakatsuki A, Ishibashi S, Yamashita S, J Atheroscler Thromb 2012 19 1043 1060 10.5551/jat.14621 23095242
20. Japan Atherosclerosis Society, Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012 Tokyo 2012
21. Challenges of PAS therapy for coronary atherosclerotic plaque reversal [abstract]. Adhikari BK, Meng X, Heart 2012 98 167
22. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. Usui S, Hara Y, Hosaki S, Okazaki M, J Lipid Res 2002 43 805 814 11971952 (Pubitemid 34477908)
23. Cilostazol inhibits accumulation of triglyceride in aorta and platelet aggregation in cholesterol-fed rabbits. Ito H, Uehara K, Matsumoto Y, Hashimoto A, Nagano C, Niimi M, Miyakoda G, Nagano K, PLoS One 2012 7 39374 10.1371/journal.pone.0039374 22761774
24. High-fat diet without excess calories induces metabolic disorders and enhances atherosclerosis in rabbits. Waqar AB, Koike T, Yu Y, Inoue T, Aoki T, Liu E, Fan J, Atherosclerosis 2010 213 148 155 10.1016/j.atherosclerosis.2010. 07.051 20832799
25. Practical method for plasma lipoprotein analysis. Hatch FT, Adv Lipid Res 1968 6 1 68 4179999
26. Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits. Wang Y, Niimi M, Nishijima K, Waqar AB, Yu Y, Koike T, Kitajima S, Liu E, Inoue T, Kohashi M, Keyamura Y, Yoshikawa T, Zhang J, Ma L, Zha X, Watanabe T, Asada Y, Chen YE, Fan J, Arterioscler Thromb Vasc Biol 2013 33 224 231 10.1161/ATVBAHA.112.300445 23241412